Savara Inc. Aktie
3,82 €
Deine Einschätzung
Savara Inc. Aktie
Was spricht für und gegen Savara Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Savara Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Savara Inc. | 0,53 % | 8,52 % | -0,52 % | 31,72 % | -11,57 % | 182,96 % | 60,88 % |
Avid Bioservices Inc | 2,33 % | -1,49 % | -9,59 % | -46,34 % | 8,20 % | -70,27 % | 23,69 % |
Rockwell Medical Inc. | -3,77 % | -8,47 % | -2,44 % | -63,32 % | -10,21 % | -79,87 % | -94,49 % |
Gritstone Oncology Inc | 1,65 % | -20,44 % | -21,78 % | -69,87 % | -71,10 % | -92,98 % | - |
Kommentare
News
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow